Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06984640 · ClinicalTrials.gov registry record · NA
Curcumin Supplementation for the Improvement of Diabetes-related Outcomes
A NA study of Over Age 60 and Prediabetes or Overweight, sponsored by Oklahoma State University.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06984640: Completed NA study of Over Age 60 and Prediabetes or Overweight, sponsored by Oklahoma State University.
NCT06984640 is a NA study of Over Age 60 and Prediabetes or Overweight that has completed, run by Oklahoma State University. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06984640, a NA study of Over Age 60 and Prediabetes or Overweight, has completed, sponsored by Oklahoma State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about, test, and compare health outcomes of curcumin supplementation (400 mg). Two primary hypotheses are: 1. Curcumin supplementation will improve glycemic control in older adults with pre-diabetic conditions over a 12-week period. \* Rationale: Curcumin has been shown to enhance insulin sensitivity, reduce fasting blood glucose, and lower HbA1c levels in preclinical and clinical studies. This hypothesis will be tested by measuring changes in fasting glucose, insulin levels, and diabetic biomarkers from baseline (Week 0) to Week 12. 2. Curcumin supplementation will beneficially alter gut microbiota composition and diversity, which is associated with improved metabolic outcomes in older adults with pre-diabetes. * Rationale: Curcumin is known to possess prebiotic-like properties and can influence gut microbial populations. By analyzing stool samples using metagenomic sequencing, this hypothesis will evaluate whether curcumin intake leads to increased abundance of beneficial bacteria (e.g., Akkermansia, Faecalibacterium) and decreased pathogenic taxa, alongside improved metabolic markers.
Primary Outcome
Using a standard scale, body weight in kg was assessed
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Curcumin
Study Locations (1)
Oklahoma
- Laboratory for Applied Nutrition and Exercise Science (LANES) - Stillwater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-03-16 |
| Est. Completion | 2025-02-13 |
| Phase | NA |
What the finished NCT06984640 record still lists
NCT06984640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Over Age 60 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06984640 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06984640 about?
NCT06984640 is a clinical study titled "Curcumin Supplementation for the Improvement of Diabetes-related Outcomes". The goal of this clinical trial is to learn about, test, and compare health outcomes of curcumin supplementation (400 mg). Two primary hypotheses are: 1. Curcumin supplementation will improve glycemic control in older adults with pre-diabetic conditions over a 12-week period. \* Rationale: Curc...
What is the current status of trial NCT06984640?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2023-03-16. Estimated completion is 2025-02-13.
What conditions does trial NCT06984640 study?
This clinical trial studies the following conditions: Over Age 60, Prediabetes or Overweight.
What interventions are being tested in trial NCT06984640?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Curcumin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06984640?
This trial is sponsored by Oklahoma State University, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06984640 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06984640's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI